ARCH Arch Biopartners Inc.
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Arch Biopartners (CVE: ARCH)
›
Arch Biopartners (CVE: ARCH) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.8800 CAD on 19 November 2026, down 10.2% over 52 weeks. Its 52-week range is 0.3900 CAD to 1.450 CAD: the price is 39.3% below the high and 125.6% above the low.
Its market capitalisation is 59.78M CAD.
Arch Biopartners reports return on equity of 40.0% and an operating margin of 0.0%.
Its debt exceeds its cash by 2.72M CAD. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health. The next earnings report is expected on 28 January 2027.